Director Kira Sheinerman Discloses 51.56% Control Stake in Niki BioSolutions Following Merger
NIKI sits 20% above its 52-week low of $7.01.
Summary
Director Kira Sheinerman reports a 51.56% stake in Niki BioSolutions, acquired via the DiamiR Biosciences merger. The accompanying Stockholders Agreement grants her board nomination rights and veto power over key decisions, cementing her control.
Key Events · Ownership and Investor Activity · NIKI
-
Control Stake Acquired via Merger
Kira Sheinerman received 1,515,293 shares (51.56% of outstanding) as non-cash merger consideration for her DiamiR Biosciences shares, giving her majority voting control.
-
Governance Rights Secured
A Stockholders Agreement grants Sheinerman the right to designate two board nominees while owning ≥36% of shares, and one nominee at ≥25%. She also holds consent rights over significant corporate actions while her stake exceeds 25%.
-
Merger Consummated, Company Renamed
The merger closed July 20, 2026, with Aptorum Group Limited domesticating as a Delaware corporation and renaming to Niki BioSolutions, now trading on Nasdaq under ticker NIKI.
-
Lock-Up Restriction
The Stockholders Agreement restricts transfers of Sheinerman's shares for six months following the effective date, limiting immediate liquidity.
Analysis · NIKI · Industrial Applications And Services
Kira Sheinerman, a director of Niki BioSolutions, now controls 51.56% of the company's outstanding shares after receiving them as merger consideration in the DiamiR Biosciences deal. This is not a market purchase — the shares were issued in exchange for her DiamiR stock — but the resulting concentration of voting power and the attached Stockholders Agreement give her significant influence over board composition and major corporate actions. For a micro-cap company with a market cap around $6.8 million, a single insider holding majority voting control reshapes the governance landscape entirely.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 35.8% of the 1045 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NIKI was trading at $8.38 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $6.8M. The 52-week trading range was $7.01 to $447.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.